Fig. 2: Genetic and pharmacological antagonism of ANTXR1 improves outcomes post-MI.
From: ANTXR1 blockade enhances cardiac function in preclinical models of heart failure
a, Echocardiography showing left ventricular ejection fraction (EF%) and fractional shortening (FS%) 28 days post-MI in Antxr1 WT and KO mice. n = 5 per group (baseline), or 6 (KO) or 8 (WT) per group (day 28). b, Representative Masson’s trichrome stain of Antxr1 WT and KO heart 28 days post-MI. c, Quantification of infarct area from hearts stained as shown in b. n = 3 (WT) or 6 (KO) per group. d, Experimental design for MI model with T8Ab treatment. Vehicle (control) or T8Ab treatments (orange arrowheads) began 1 day post-MI. e, Representative echocardiography tracings at baseline and 42 days post-MI with and without T8Ab. f,g, EF% (f) and FS% (g) at baseline and day 1 or 42 post-MI. n = 18 per group. h, Kaplan–Meier survival analysis post-MI in mice treated with vehicle or T8Ab. P value was from a log-rank (Mantel–Cox) test. n = 17 (vehicle) or 18 (T8Ab). Data are shown as mean ± s.e.m. (a,f,g) or mean ± s.d. (c); statistical analysis was performed using one-way ANOVA with Tukey’s multiple-comparisons test (a,f,g) or Welch’s two-tailed t-test (c). NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. The syringe in d created with BioRender.com.
